{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:08:19Z","timestamp":1791644899665,"version":"4.3.4"},"reference-count":187,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Invasive candidiasis (IC) is a serious infection caused by several Candida species, and the most common fungal disease in hospitals in high-income countries. Despite overall improvements in health systems and ICU care in the last few decades, as well as the development of different antifungals and microbiological techniques, mortality rates in IC have not substantially improved. The aim of this review is to summarize the main issues underlying the management of adults affected by IC, focusing on specific forms of the infection: IC developed by ICU patients, IC observed in haematological patients, breakthrough candidaemia, sanctuary site candidiasis, intra-abdominal infections and other challenging infections.<\/jats:p>\n                  <jats:p>Several key challenges need to be tackled to improve the clinical management and outcomes of IC patients. These include the lack of global epidemiological data for IC, the limitations of the diagnostic tests and risk scoring tools currently available, the absence of standardized effectiveness outcomes and long-term data for IC, the timing for the initiation of antifungal therapy and the limited recommendations on the optimal step-down therapy from echinocandins to azoles or the total duration of therapy.<\/jats:p>\n                  <jats:p>The availability of new compounds may overcome some of the challenges identified and increase the existing options for management of chronic Candida infections and ambulant patient treatments. However, early identification of patients that require antifungal therapy and treatment of sanctuary site infections remain a challenge and will require further innovations.<\/jats:p>","DOI":"10.1093\/jac\/dkad139","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:44:00Z","timestamp":1684863840000},"page":"1569-1585","source":"Crossref","is-referenced-by-count":201,"title":["Invasive candidiasis: current clinical challenges and unmet needs in adult populations"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, IDIBAPS, CIBERINF, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-4890","authenticated-orcid":false,"given":"Patrick M","family":"Honore","sequence":"additional","affiliation":[{"name":"CHU UCL Godinne Namur, UCL Louvain Medical School , Namur , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-0217","authenticated-orcid":false,"given":"Pedro","family":"Puerta-Alcalde","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, IDIBAPS, CIBERINF, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0683","authenticated-orcid":false,"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, IDIBAPS, CIBERINF, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Symmetron Ltd , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5186-3792","authenticated-orcid":false,"given":"Daniela C","family":"Gon\u00e7alves-Bradley","sequence":"additional","affiliation":[{"name":"Symmetron Ltd , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E","family":"Verweij","sequence":"additional","affiliation":[{"name":"Radboudumc-CWZ Center of Expertise for Mycology , Nijmegen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"2023070504550527100_dkad139-B1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2023070504550527100_dkad139-B2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","article-title":"Invasive candidiasis in critical care: challenges and future directions","volume":"46","author":"Logan","year":"2020","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2023070504550527100_dkad139-B4","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cix1095","article-title":"Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel","volume":"66","author":"Clancy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/mmy\/myt025","article-title":"Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia","volume":"52","author":"Martinez-Jimenez","year":"2014","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B6","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2023070504550527100_dkad139-B7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.idc.2021.03.007","article-title":"Candidemia and invasive candidiasis","volume":"35","author":"McCarty","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2023070504550527100_dkad139-B8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/myc.13054","article-title":"Changes in the relative prevalence of candidaemia due to non-albicans Candida species in adult in-patients: a systematic review, meta-analysis and meta-regression","volume":"63","author":"Giacobbe","year":"2020","journal-title":"Mycoses"},{"key":"2023070504550527100_dkad139-B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008921","article-title":"Candida auris: epidemiology, biology, antifungal resistance, and virulence","volume":"16","author":"Du","year":"2020","journal-title":"PLoS Pathog"},{"key":"2023070504550527100_dkad139-B10","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/S2666-5247(22)00203-8","article-title":"The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly","volume":"3","author":"Zhang","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023070504550527100_dkad139-B11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251170","article-title":"Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis","volume":"16","author":"Musuuza","year":"2021","journal-title":"PLoS ONE"},{"key":"2023070504550527100_dkad139-B12","doi-asserted-by":"crossref","first-page":"O50","DOI":"10.1111\/1469-0691.12312","article-title":"A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies","volume":"20","author":"Gamaletsou","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B13","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2023070504550527100_dkad139-B14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the transplant-associated infection surveillance network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B15","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"2023070504550527100_dkad139-B16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4161\/viru.1.5.12796","article-title":"Candida infection and colonization among trauma patients","volume":"1","author":"Manolakaki","year":"2010","journal-title":"Virulence"},{"key":"2023070504550527100_dkad139-B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4161\/viru.22913","article-title":"Candida albicans pathogenicity mechanisms","volume":"4","author":"Mayer","year":"2013","journal-title":"Virulence"},{"key":"2023070504550527100_dkad139-B18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/myc.13290","article-title":"Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: a systematic review and network meta-analysis","volume":"64","author":"Demir","year":"2021","journal-title":"Mycoses"},{"key":"2023070504550527100_dkad139-B19","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01909-17","article-title":"Diagnosing invasive candidiasis","volume":"56","author":"Clancy","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B20","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/jac\/dkx444","article-title":"Changes in the epidemiological landscape of invasive candidiasis","volume":"73","author":"Lamoth","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023070504550527100_dkad139-B21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"2023070504550527100_dkad139-B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1469-0691.12038","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures","volume":"18","author":"Cuenca-Estrella","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 7","key":"2023070504550527100_dkad139-B23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Ismail","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"2023070504550527100_dkad139-B25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10096-013-1944-3","article-title":"Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species","volume":"33","author":"Drgona","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"2023070504550527100_dkad139-B27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13643-017-0625-1","article-title":"A comparison of results of empirical studies of supplementary search techniques and recommendations in review methodology handbooks: a methodological review","volume":"6","author":"Cooper","year":"2017","journal-title":"Syst Rev"},{"key":"2023070504550527100_dkad139-B28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.idc.2015.10.013","article-title":"Invasive candidiasis","volume":"30","author":"McCarty","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2023070504550527100_dkad139-B29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijantimicag.2013.09.005","article-title":"Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities","volume":"43","author":"Wisplinghoff","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023070504550527100_dkad139-B30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/380637","article-title":"Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991\u20132000","volume":"38","author":"Marchetti","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B31","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"2023070504550527100_dkad139-B32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B34","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00869-21","article-title":"Evaluation of the performance of the associates of Cape Cod STAT assay for the diagnosis of invasive fungal disease in critical-care patients with COVID-19","volume":"59","author":"White","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s00134-013-3109-3","article-title":"A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts","volume":"39","author":"Bassetti","year":"2013","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","article-title":"A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/13693786.2011.587211","article-title":"Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors","volume":"50","author":"Zirkel","year":"2012","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B38","doi-asserted-by":"crossref","first-page":"87.e1","DOI":"10.1016\/j.cmi.2014.08.011","article-title":"Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006\u20132008)","volume":"21","author":"Klingspor","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","article-title":"Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY antifungal surveillance program (2013)","volume":"85","author":"Castanheira","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JCM.01398-10","article-title":"Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program (2008 to 2009)","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/JCM.36.2.329-334.1998","article-title":"Candida dubliniensis: characteristics and identification","volume":"36","author":"Sullivan","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J Infect Dis"},{"key":"2023070504550527100_dkad139-B43","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00029-17","article-title":"Candida auris: a review of the literature","volume":"31","author":"Jeffery-Smith","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2023070504550527100_dkad139-B44","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01588-17","article-title":"Candida auris: an emerging fungal pathogen","volume":"56","author":"Spivak","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B45","first-page":"1","article-title":"Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis","volume":"54","author":"Pfaller","year":"2016","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13054-016-1313-6","article-title":"Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy","volume":"20","author":"Calandra","year":"2016","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3201\/eid2301.161198","article-title":"Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002\u20132012(1)","volume":"23","author":"Strollo","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2023070504550527100_dkad139-B48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1186\/s12879-019-4419-z","article-title":"Pooled analysis of T2 Candida for rapid diagnosis of candidiasis","volume":"19","author":"Tang","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023070504550527100_dkad139-B50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10096-016-2658-0","article-title":"Invasive candidiasis: from mycobiome to infection, therapy, and prevention","volume":"35","author":"Lagunes","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases","volume":"15","author":"Schelenz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2023070504550527100_dkad139-B52","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/cid\/cit006","article-title":"Finding the \u2018missing 50%\u2019 of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care","volume":"56","author":"Clancy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B53","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1093\/jac\/dkt285","article-title":"Usefulness of time-to-positivity in aerobic and anaerobic vials to predict the presence of Candida glabrata in patients with candidaemia","volume":"68","author":"Cobos-Trigueros","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2023070504550527100_dkad139-B54","doi-asserted-by":"crossref","first-page":"R222","DOI":"10.1186\/cc9365","article-title":"The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia","volume":"14","author":"Mikulska","year":"2010","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.diagmicrobio.2018.10.017","article-title":"Diagnostic accuracy of Candida albicans germ tube antibody for invasive candidiasis: systematic review and meta-analysis","volume":"93","author":"Wei","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/jof6030101","article-title":"Molecular methods for the diagnosis of invasive candidiasis","volume":"6","author":"Camp","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2023070504550527100_dkad139-B57","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00134-017-4932-8","article-title":"Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial","volume":"43","author":"Rouz\u00e9","year":"2017","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/JCM.01602-10","article-title":"PCR diagnosis of invasive candidiasis: systematic review and meta-analysis","volume":"49","author":"Avni","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14787210.2021.1964954","article-title":"T2MR can be used as a non-culture-based test together with biomarkers to improve detection of Candida in the bloodstream and reduce time delay in treating invasive candidiasis","volume":"20","author":"Honore","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023070504550527100_dkad139-B60","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab080","article-title":"Performance of repeated measures of (1-3)-beta-D-glucan, mannan antigen, and antimannan antibodies for the diagnosis of invasive candidiasis in ICU patients: a preplanned ancillary analysis of the EMPIRICUS randomized clinical trial","volume":"8","author":"Dupuis","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023070504550527100_dkad139-B61","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00000658-199412000-00008","article-title":"Candida colonization and subsequent infections in critically ill surgical patients","volume":"220","author":"Pittet","year":"1994","journal-title":"Ann Surg"},{"key":"2023070504550527100_dkad139-B62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","article-title":"A bedside scoring system (\u2018Candida score\u2019) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization","volume":"34","author":"Leon","year":"2006","journal-title":"Crit Care Med"},{"key":"2023070504550527100_dkad139-B63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10096-007-0270-z","article-title":"Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting","volume":"26","author":"Ostrosky-Zeichner","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.chest.2021.08.081","article-title":"Risk factors for invasive candida infection in critically ill patients\u2014a systematic review and meta-analysis","volume":"161","author":"Thomas-Ruddel","year":"2022","journal-title":"Chest"},{"key":"2023070504550527100_dkad139-B65","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13054-016-1521-0","article-title":"Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?","volume":"20","author":"Cortegiani","year":"2016","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B66","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"2023070504550527100_dkad139-B67","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.100.6.1619","article-title":"The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults","volume":"100","author":"Knaus","year":"1991","journal-title":"Chest"},{"key":"2023070504550527100_dkad139-B68","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/01.CCM.0000215112.84523.F0","article-title":"Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients","volume":"34","author":"Zimmerman","year":"2006","journal-title":"Crit Care Med"},{"key":"2023070504550527100_dkad139-B69","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00134-005-2763-5","article-title":"SAPS 3\u2014from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission","volume":"31","author":"Moreno","year":"2005","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B70","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s00134-005-2762-6","article-title":"SAPS 3\u2014from evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description","volume":"31","author":"Metnitz","year":"2005","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13613-015-0103-7","article-title":"Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study","volume":"6","author":"Leroy","year":"2016","journal-title":"Ann Intensive Care"},{"key":"2023070504550527100_dkad139-B72","doi-asserted-by":"crossref","first-page":"R249","DOI":"10.1186\/cc10507","article-title":"Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1\u2013&gt;3)-beta-D-glucan assay, Candida score, and colonization index","volume":"15","author":"Posteraro","year":"2011","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B73","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1097\/CCM.0000000000000208","article-title":"Polymorphisms in tumor necrosis factor-alpha increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*","volume":"42","author":"Wojtowicz","year":"2014","journal-title":"Crit Care Med"},{"key":"2023070504550527100_dkad139-B74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00134-014-3355-z","article-title":"Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later","volume":"40","author":"Eggimann","year":"2014","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13054-019-2525-3","article-title":"Need for expanded Candida score for empiric antifungal use in medically critically ill patients?","volume":"23","author":"Laine","year":"2019","journal-title":"Crit Care"},{"issue":"Suppl 7","key":"2023070504550527100_dkad139-B76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B77","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2023070504550527100_dkad139-B78","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"2023070504550527100_dkad139-B79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-11-261","article-title":"Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome","volume":"11","author":"Reboli","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2023070504550527100_dkad139-B80","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B81","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B82","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B83","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B84","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2023070504550527100_dkad139-B85","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"2023070504550527100_dkad139-B86","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.diagmicrobio.2011.03.002","article-title":"Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria","volume":"70","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B87","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","article-title":"Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis","volume":"89","author":"Safdar","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"2023070504550527100_dkad139-B88","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00134-014-3400-y","article-title":"Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period","volume":"40","author":"Colombo","year":"2014","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B89","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10096-018-3285-8","article-title":"Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship","volume":"37","author":"Mellinghoff","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B90","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.01.013","article-title":"Antifungal stewardship in a tertiary-care institution: a bedside intervention","volume":"21","author":"Valerio","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B91","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/jac\/dkw391","article-title":"The current treatment landscape: the need for antifungal stewardship programmes","volume":"71","author":"Mu\u00f1oz","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023070504550527100_dkad139-B92","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/13693786.2010.512300","article-title":"Early treatment of candidemia in adults: a review","volume":"49","author":"Ostrosky-Zeichner","year":"2011","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B93","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B94","article-title":"Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients","volume":"2016","author":"Cortegiani","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2023070504550527100_dkad139-B95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jinf.2015.09.041","article-title":"Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.\u2014trends over 10 years","volume":"72","author":"Bailly","year":"2016","journal-title":"J Infect"},{"key":"2023070504550527100_dkad139-B96","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2016.14655","article-title":"Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial","volume":"316","author":"Timsit","year":"2016","journal-title":"JAMA"},{"key":"2023070504550527100_dkad139-B97","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153247","article-title":"Intra-abdominal candidiasis: the importance of early source control and antifungal treatment","volume":"11","author":"Vergidis","year":"2016","journal-title":"PLoS ONE"},{"key":"2023070504550527100_dkad139-B99","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019729","article-title":"Fungal biofilms, drug resistance, and recurrent infection","volume":"4","author":"Desai","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2023070504550527100_dkad139-B100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fcimb.2020.00166","article-title":"Genotyping reveals high clonal diversity and widespread genotypes of Candida causing candidemia at distant geographical areas","volume":"10","author":"Guinea","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2023070504550527100_dkad139-B101","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/528521","article-title":"Fungal biofilm resistance","volume":"2012","author":"Ramage","year":"2012","journal-title":"Int J Microbiol"},{"key":"2023070504550527100_dkad139-B102","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/MMBR.64.4.847-867.2000","article-title":"Microbial biofilms: from ecology to molecular genetics","volume":"64","author":"Davey","year":"2000","journal-title":"Microbiol Mol Biol Rev"},{"key":"2023070504550527100_dkad139-B103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jac\/dkr473","article-title":"Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials?","volume":"67","author":"Toulet","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2023070504550527100_dkad139-B104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fmed.2018.00028","article-title":"Candida biofilms: threats, challenges, and promising strategies","volume":"5","author":"Cavalheiro","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2023070504550527100_dkad139-B105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/5584_2019_400","article-title":"Novel therapies for biofilm-based Candida spp. Infections","volume":"1214","author":"Cernakova","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2023070504550527100_dkad139-B106","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.diagmicrobio.2019.04.016","article-title":"T2 Candida versus beta-D-glucan to facilitate antifungal discontinuation in the intensive care unit","volume":"95","author":"Gill","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B107","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab250","article-title":"Early stepdown from echinocandin to fluconazole treatment in candidemia: a post hoc analysis of three cohort studies","volume":"8","author":"Moreno-Garcia","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023070504550527100_dkad139-B108","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01756-17","article-title":"Efficacy of T2 magnetic resonance assay in monitoring candidemia after initiation of antifungal therapy: the serial therapeutic and antifungal monitoring protocol (STAMP) trial","volume":"56","author":"Mylonakis","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B109","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B110","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3390\/microorganisms9102068","article-title":"Pharmacokinetic variability and target attainment of fluconazole in critically ill patients","volume":"9","author":"Van Daele","year":"2021","journal-title":"Microorganisms"},{"key":"2023070504550527100_dkad139-B111","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QCO.0000000000000740","article-title":"Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions","volume":"34","author":"Lewis","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"2023070504550527100_dkad139-B112","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY antifungal surveillance program: results for Candida Species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023070504550527100_dkad139-B113","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/antibiotics9120877","article-title":"Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium","volume":"9","author":"Arastehfar","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2023070504550527100_dkad139-B114","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/jof4030105","article-title":"Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata","volume":"4","author":"Healey","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2023070504550527100_dkad139-B115","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03364-19","article-title":"Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses","volume":"11","author":"Chow","year":"2020","journal-title":"mBio"},{"key":"2023070504550527100_dkad139-B116","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B117","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006290","article-title":"Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally","volume":"13","author":"Chowdhary","year":"2017","journal-title":"PLoS Pathog"},{"key":"2023070504550527100_dkad139-B119","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/ciw696","article-title":"Emergence of Candida auris: an international call to arms","volume":"64","author":"Clancy","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B120","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts\u2014Fourth Edition: M27","author":"CLSI","year":"2017"},{"key":"2023070504550527100_dkad139-B121","author":"Arendrup","year":"2020"},{"key":"2023070504550527100_dkad139-B122","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14787210.2020.1760841","article-title":"Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time","volume":"18","author":"Knabl","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023070504550527100_dkad139-B123","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/jof7080597","article-title":"Dynamics and predictors of mortality due to Candidemia caused by different Candida species: comparison of Intensive Care Unit-Associated Candidemia (ICUAC) and non-ICUAC","volume":"7","author":"Kwon","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2023070504550527100_dkad139-B124","first-page":"5","article-title":"Plasma pharmacokinetics of antimicrobial agents in critically ill patients","volume":"8","author":"Pea","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"2023070504550527100_dkad139-B125","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00134-006-0397-x","article-title":"Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing","volume":"32","author":"Bouman","year":"2006","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B126","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s00134-003-1980-z","article-title":"Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration","volume":"29","author":"Yagasaki","year":"2003","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B127","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/jof6040286","article-title":"Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids","volume":"6","author":"Riche","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2023070504550527100_dkad139-B128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jof6040211","article-title":"COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?","volume":"6","author":"Arastehfar","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2023070504550527100_dkad139-B129","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00134-012-2616-y","article-title":"Value of beta-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions","volume":"38","author":"Leon","year":"2012","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/viru.26187","article-title":"Invasive candidiasis as a cause of sepsis in the critically ill patient","volume":"5","author":"Delaloye","year":"2014","journal-title":"Virulence"},{"key":"2023070504550527100_dkad139-B131","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13054-020-2766-1","article-title":"Risk factors for candidemia: a prospective matched case-control study","volume":"24","author":"Poissy","year":"2020","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B132","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s13054-014-0590-1","article-title":"Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"2023070504550527100_dkad139-B133","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00134-017-4743-y","article-title":"The risk and clinical outcome of candidemia depending on underlying malignancy","volume":"43","author":"Lortholary","year":"2017","journal-title":"Intensive Care Med"},{"key":"2023070504550527100_dkad139-B134","first-page":"3221","article-title":"European Guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023070504550527100_dkad139-B135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B136","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/502104","article-title":"Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity","volume":"23","author":"Kontoyiannis","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023070504550527100_dkad139-B137","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V87.2.838.bloodjournal872838","article-title":"Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies","volume":"87","author":"Girmenia","year":"1996","journal-title":"Blood"},{"key":"2023070504550527100_dkad139-B138","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1086\/320757","article-title":"Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia","volume":"32","author":"Uzun","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B139","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/JCM.02390-09","article-title":"Breakthrough invasive candidiasis in patients on micafungin","volume":"48","author":"Pfeiffer","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2023070504550527100_dkad139-B140","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/AAC.02189-13","article-title":"Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin","volume":"58","author":"Bizerra","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504550527100_dkad139-B141","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/mmy\/myx077","article-title":"Breakthrough candidemia after the introduction of broad spectrum antifungal agents: a 5-year retrospective study","volume":"56","author":"Breda","year":"2018","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B142","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cmi.2015.09.029","article-title":"Breakthrough candidaemia in the era of broad-spectrum antifungal therapies","volume":"22","author":"Cuervo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B143","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10096-002-0697-1","article-title":"Risk factors for breakthrough candidemia","volume":"21","author":"Nucci","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B144","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jinf.2017.12.018","article-title":"Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study","volume":"76","author":"Orasch","year":"2018","journal-title":"J Infect"},{"key":"2023070504550527100_dkad139-B145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0732-8893(00)00140-1","article-title":"The central nervous system and infection by Candida species","volume":"37","author":"Sanchez-Portocarrero","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B146","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/clinids\/21.2.323","article-title":"Meningitis caused by Candida species: an emerging problem in neurosurgical patients","volume":"21","author":"Nguyen","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B147","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/513746","article-title":"Candidal meningitis in HIV-infected patients: analysis of 14 cases","volume":"25","author":"Casado","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B148","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/13693786.2013.789566","article-title":"Candida cerebral abscesses: a case report and review of the literature","volume":"51","author":"Fennelly","year":"2013","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B149","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1111\/j.1469-0691.2012.03764.x","article-title":"Diagnosis, management and outcome of Candida endocarditis","volume":"18","author":"Lefort","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023070504550527100_dkad139-B150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005293","article-title":"CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system","volume":"11","author":"Drummond","year":"2015","journal-title":"PLoS Pathog"},{"key":"2023070504550527100_dkad139-B151","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10096-008-0466-x","article-title":"Candida infective endocarditis","volume":"27","author":"Baddley","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B152","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/cid\/cix913","article-title":"Prosthetic valve Candida spp. endocarditis: new insights into long-term prognosis-the ESCAPE study","volume":"66","author":"Rivoisy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B153","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1474-4422(18)30030-9","article-title":"Advances in the diagnosis and treatment of fungal infections of the CNS","volume":"17","author":"Schwartz","year":"2018","journal-title":"Lancet Neurol"},{"key":"2023070504550527100_dkad139-B154","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/mmy\/myaa051","article-title":"Central nervous system candidiasis beyond neonates: lessons from a nationwide study","volume":"59","author":"Chaussade","year":"2021","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/00365540310017573","article-title":"Clinical characteristics, treatment and prognostic factors of candidal meningitis in a teaching hospital in Taiwan","volume":"36","author":"Chen","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"2023070504550527100_dkad139-B156","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/clinids\/6.6.791","article-title":"Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis","volume":"6","author":"Smego RA","year":"1984","journal-title":"Rev Infect Dis"},{"key":"2023070504550527100_dkad139-B157","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1128\/AAC.00949-10","article-title":"Human tissue distribution of voriconazole","volume":"55","author":"Weiler","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504550527100_dkad139-B158","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/21548331.2018.1538623","article-title":"Candidemia from urinary tract source: the challenge of candiduria","volume":"46","author":"Peman","year":"2018","journal-title":"Hosp Pract (1995)"},{"key":"2023070504550527100_dkad139-B159","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cix033","article-title":"Echinocandins compared to fluconazole for candidemia of a urinary tract source: a propensity score analysis","volume":"64","author":"Cuervo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1086\/313580","article-title":"Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) mycoses study group","volume":"30","author":"Sobel","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B161","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.05.010","article-title":"Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp","volume":"48","author":"Grau","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2023070504550527100_dkad139-B162","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1586\/eri.11.139","article-title":"Fungal endophthalmitis","volume":"9","author":"Chhablani","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023070504550527100_dkad139-B163","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.31.1.6","article-title":"Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis","volume":"31","author":"Savani","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504550527100_dkad139-B164","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1086\/514973","article-title":"Treatment options for candidal endophthalmitis [editorial comment]","volume":"27","author":"Barza","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B165","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archopht.1990.01070090108050","article-title":"Ocular uptake of fluconazole following oral administration","volume":"108","author":"O\u2019Day","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"2023070504550527100_dkad139-B166","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cid\/cir355","article-title":"Ocular manifestations of candidemia","volume":"53","author":"Lashof","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B167","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1086\/317550","article-title":"Fungal endocarditis: evidence in the world literature, 1965\u20131995","volume":"32","author":"Ellis","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B168","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1439-0507.2010.01884.x","article-title":"Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis","volume":"54","author":"Boland","year":"2011","journal-title":"Mycoses"},{"key":"2023070504550527100_dkad139-B169","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/myc.13398","article-title":"Clinical features, diagnosis and treatment outcome of fungal endocarditis: a systematic review of reported cases","volume":"65","author":"Meena","year":"2022","journal-title":"Mycoses"},{"key":"2023070504550527100_dkad139-B170","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14787210.2017.1372749","article-title":"Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian study of endocarditis","volume":"15","author":"Giuliano","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023070504550527100_dkad139-B171","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/mmy\/myz104","article-title":"Risk factors predicting Candida infective endocarditis in patients with candidemia","volume":"58","author":"Foong","year":"2020","journal-title":"Med Mycol"},{"key":"2023070504550527100_dkad139-B172","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/cid\/cis660","article-title":"Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970\u20132011)","volume":"55","author":"Gamaletsou","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023070504550527100_dkad139-B173","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10096-013-1939-0","article-title":"Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH alliance(R) registry","volume":"33","author":"Neofytos","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B174","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diagmicrobio.2012.02.004","article-title":"Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature","volume":"73","author":"Slenker","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B175","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019735","article-title":"Prosthetic joint infection due to Candida species: case series and review of literature","volume":"99","author":"Saconi","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2023070504550527100_dkad139-B176","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11046-018-0286-1","article-title":"Prosthetic joint infections caused by Candida species: a systematic review and a case series","volume":"184","author":"Lee","year":"2019","journal-title":"Mycopathologia"},{"key":"2023070504550527100_dkad139-B177","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000520111","article-title":"Candida pneumonia: an innocent bystander or a silent killer?","volume":"31","author":"Meena","year":"2022","journal-title":"Med Princ Pract"},{"key":"2023070504550527100_dkad139-B178","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijantimicag.2013.08.010","article-title":"Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives","volume":"43","author":"Neoh","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023070504550527100_dkad139-B179","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12879-017-2573-8","article-title":"Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species","volume":"17","author":"Ou","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2023070504550527100_dkad139-B180","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10096-014-2230-8","article-title":"Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole","volume":"34","author":"Heimann","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023070504550527100_dkad139-B181","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2023070504550527100_dkad139-B182","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023070504550527100_dkad139-B183","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2023070504550527100_dkad139-B184","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02476-20","article-title":"Therapeutic potential of fosmanogepix (APX001) for intra-abdominal candidiasis: from lesion penetration to efficacy in a mouse model","volume":"65","author":"Lee","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504550527100_dkad139-B185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00656-20","article-title":"Manogepix (APX001A) in vitro activity against Candida auris: head-to-head comparison of EUCAST and CLSI MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504550527100_dkad139-B186","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02198-19","article-title":"The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against Candida auris","volume":"64","author":"Wiederhold","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504550527100_dkad139-B187","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/jof8101077","article-title":"Antifungal combinations against Candida species: from bench to bedside","volume":"8","author":"Fioriti","year":"2022","journal-title":"J Fungi (Basel)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/7\/1569\/50792215\/dkad139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/7\/1569\/50792215\/dkad139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:56:02Z","timestamp":1688529362000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/7\/1569\/7176280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":187,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,5,23]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad139","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,5,23]]}}}